TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF GLOBAL PCR MULTIPLEX ASSAYS MARKET 22
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GLOBAL PCR MULTIPLEX ASSAYS MARKET: GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.7 DBMR MARKET POSITION GRID 33
2.8 MARKET APPLICATION COVERAGE GRID 34
2.9 DBMR VENDOR SHARE ANALYSIS 35
2.10 MULTIVARIATE MODELING 36
2.11 PRODUCTS LIFELINE CURVE 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 MARKET OVERVIEW 38
3.1 DRIVERS 40
3.1.1 TECHNOLOGICAL ADVANCEMENTS OF PCR MULTIPLEX ASSAYS 40
3.1.2 INTRODUCTION OF NOVEL AUTOMATED SYSTEMS 40
3.1.3 GROWING RESEARCH AND DEVELOPMENT FOR DRUG DISCOVERY 41
3.1.4 USE OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS 42
3.2 RESTRAINTS 44
3.2.1 HIGH COST OF THE MULTIPLEX ASSAYS 44
3.2.2 STRINGENT REGULATIONS AND STANDARDS 44
3.3 OPPORTUNITIES 45
3.3.1 GROWING VALIDATION OF BIOMARKERS IN MOLECULAR AND PROTEIN DIAGNOSTICS 45
3.3.2 BUSINESS EXPANSION FOR DEVELOPMENT OF PCR MULTIPLEX ASSAYS 46
3.4 CHALLENGE 47
3.4.1 LACK OF PROFICIENT LABOUR TO HANDLE ADVANCED PROCEDURES 47
4 EXECUTIVE SUMMARY 48
5 PREMIUM INSIGHTS 51
6 GLOBAL PCR MULTIPLEX ASSAYS MARKET, BY PRODUCTS & SERVICES 53
6.1 OVERVIEW 54
6.2 REAGENTS & CONSUMABLES 55
6.3 INSTRUMENTS & ACCESSORIES 55
6.4 SOFTWARE AND SERVICES 56
7 GLOBAL PCR MULTIPLEX ASSAYS MARKET, BY APPLICATION 57
7.1 OVERVIEW 58
7.2 CLINICAL DIAGNOSTICS 59
7.2.1 CANCER 60
7.2.2 CARDIOVASCULAR DISEASES 60
7.2.3 RESPIRATORY DISEASES 60
7.2.4 METABOLISM & ENDOCRINOLOGY DISORDERS 60
7.2.5 NERVOUS SYSTEM DISORDERS 60
7.2.6 AUTOIMMUNE DISEASES 60
7.2.7 ALLERGIES 60
7.2.8 OTHERS 60
7.3 RESEARCH & DEVELOPMENT 61
7.3.1 DRUG DISCOVERY & DEVELOPMENT 61
7.3.2 BIOMARKER DISCOVERY & VALIDATION 61
8 GLOBAL PCR MULTIPLEX ASSAYS MARKET, BY END USER 62
8.1 OVERVIEW 63
8.2 HOSPITALS 64
8.3 CLINICAL LABORATORIES 64
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 65
8.5 RESEARCH INSTITUTES 65
8.6 OTHERS 66
9 GLOBAL PCR MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY 67
9.1 OVERVIEW 68
9.2 NORTH AMERICA 73
9.2.1 U.S. 78
9.2.2 CANADA 80
9.2.3 MEXICO 82
?
9.3 EUROPE 84
9.3.1 GERMANY 89
9.3.2 U.K. 91
9.3.3 FRANCE 93
9.3.4 ITALY 95
9.3.5 SPAIN 97
9.3.6 SWITZERLAND 99
9.3.7 NETHERLANDS 101
9.3.8 BELGIUM 103
9.3.9 AUSTRIA 105
9.3.10 IRELAND 107
9.3.11 REST OF EUROPE 109
9.4 ASIA-PACIFIC 110
9.4.1 CHINA 115
9.4.2 JAPAN 117
9.4.3 INDIA 119
9.4.4 AUSTRALIA 121
9.4.5 SOUTH KOREA 123
9.4.6 SINGAPORE 125
9.4.7 MALAYSIA 127
9.4.8 INDONESIA 129
9.4.9 THAILAND 131
9.4.10 PHILIPPINES 133
9.4.11 REST OF ASIA-PACIFIC 135
9.5 SOUTH AMERICA 136
9.5.1 BRAZIL 141
9.5.2 REST OF SOUTH AMERICA 143
9.6 MIDDLE EAST & AFRICA 144
9.6.1 SOUTH AFRICA 149
9.6.2 REST OF MIDDLE EAST & AFRICA 151
10 GLOBAL PCR MULTIPLEX ASSAYS MARKET, COMPANY LANDSCAPE 152
10.1 COMPANY SHARE ANALYSIS: GLOBAL 152
10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 153
10.3 COMPANY SHARE ANALYSIS: EUROPE 154
10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 155
?
11 SWOT ANALYSIS 156
11.1 STRENGTH: - SIGNIFICANT INCREASING SHARES IN MARKET FOCUSED SEGMENT 156
11.2 STRENGTH: - STRONG GLOBAL PRESENCE AND MARKET SHARE 157
11.3 WEAKNESS: - PRODUCT RECALL 158
11.4 OPPORTUNITY: - STRATEGIC INVESTMENTS 158
11.5 THREAT: - STIFF COMPETITION 159
12 COMPANY PROFILES 160
12.1 F. HOFFMANN-LA ROCHE LTD. 160
12.1.1 COMPANY SNAPSHOT 160
12.1.2 REVENUE ANALYSIS 160
12.1.3 COMPANY SHARE ANALYSIS 161
12.1.4 PRODUCT PORTFOLIO 161
12.1.5 RECENT DEVELOPMENTS 162
12.2 HOL0GIC INC 163
12.2.1 COMPANY SNAPSHOT 163
12.2.2 REVENUE ANALYSIS 163
12.2.3 COMPANY SHARE ANALYSIS 164
12.2.4 PRODUCT PORTFOLIO 164
12.2.5 RECENT DEVELOPMENTS 165
12.3 LUMINEX CORPORATION. 166
12.3.1 COMPANY SNAPSHOT 166
12.3.2 REVENUE ANALYSIS 166
12.3.3 COMPANY SHARE ANALYSIS 167
12.3.4 PRODUCT PORTFOLIO 167
12.3.5 RECENT DEVELOPMENTS 168
12.4 BECTON, DICKINSON AND COMPANY 169
12.4.1 COMPANY SNAPSHOT 169
12.4.2 REVENUE ANALYSIS 169
12.4.3 COMPANY SHARE ANALYSIS 170
12.4.4 PRODUCT PORTFOLIO 170
12.4.5 RECENT DEVELOPMENTS 171
12.5 ABBOTT 172
12.5.1 COMPANY SNAPSHOT 172
12.5.2 REVENUE ANALYSIS 172
12.5.3 PRODUCT PORTFOLIO 173
12.5.4 RECENT DEVELOPMENTS 173
?
12.6 AGENA BIOSCIENCE, INC 174
12.6.1 COMPANY SNAPSHOT 174
12.6.2 PRODUCT PORTFOLIO 174
12.6.3 RECENT DEVELOPMENT 174
12.7 AGILENT TECHNOLOGIES, INC 175
12.7.1 COMPANY SNAPSHOT 175
12.7.2 REVENUE ANALYSIS 175
12.7.3 PRODUCT PORTFOLIO 176
12.7.4 RECENT DEVELOPMENT 176
12.8 BIO-RAD LABORATORIES, INC. 177
12.8.1 COMPANY SNAPSHOT 177
12.8.2 REVENUE ANALYSIS 177
12.8.3 PRODUCT PORTFOLIO 178
12.8.4 RECENT DEVELOPMENTS 180
12.9 BIOMeRIEUX SA 181
12.9.1 COMPANY SNAPSHOT 181
12.9.2 REVENUE ANALYSIS 181
12.9.3 PRODUCT PORTFOLIO 182
12.9.4 RECENT DEVELOPMENTS 183
12.10 BIOTEK INSTRUMENTS, INC. 184
12.10.1 COMPANY SNAPSHOT 184
12.10.2 PRODUCT PORTFOLIO 184
12.10.3 RECENT DEVELOPMENT 184
12.11 DIASORIN S.P.A 185
12.11.1 COMPANY SNAPSHOT 185
12.11.2 REVENUE ANALYSIS 185
12.11.3 PRODUCT PORTFOLIO 186
12.11.4 RECENT DEVELOPMENT 187
12.12 EUROFINS SCIENTIFIC 188
12.12.1 COMPANY SNAPSHOT 188
12.12.2 REVENUE ANALYSIS 188
12.12.3 PRODUCT PORTFOLIO 189
12.12.4 RECENT DEVELOPMENT 189
12.13 ILLUMINA, INC. 190
12.13.1 COMPANY SNAPSHOT 190
12.13.2 REVENUE ANALYSIS 190
12.13.3 PRODUCT PORTFOLIO 191
12.13.4 RECENT DEVELOPMENT 191
?
12.14 OLINK 192
12.14.1 COMPANY SNAPSHOT 192
12.14.2 PRODUCT PORTFOLIO 192
12.14.3 RECENT DEVELOPMENT 192
12.15 PATHONOSTICS B.V. 193
12.15.1 COMPANY SNAPSHOT 193
12.15.2 PRODUCT PORTFOLIO 193
12.15.3 RECENT DEVELOPMENT 193
12.16 PERKINELMER INC. 194
12.16.1 COMPANY SNAPSHOT 194
12.16.2 REVENUE ANALYSIS 194
12.16.3 PRODUCT PORTFOLIO 195
12.16.4 RECENT DEVELOPMENT 195
12.17 QIAGEN 196
12.17.1 COMPANY SNAPSHOT 196
12.17.2 REVENUE ANALYSIS 196
12.17.3 PRODUCT PORTFOLIO 197
12.17.4 RECENT DEVELOPMENTS 198
12.18 QUEST DIAGNOSTICS INCORPORATED 199
12.18.1 COMPANY SNAPSHOT 199
12.18.2 REVENUE ANALYSIS 199
12.18.3 PRODUCT PORTFOLIO 200
12.18.4 RECENT DEVELOPMENT 200
12.19 RANDOX LABORATORIES LTD. 201
12.19.1 COMPANY SNAPSHOT 201
12.19.2 PRODUCT PORTFOLIO 201
12.19.3 RECENT DEVELOPMENT 201
12.20 SEEGENE INC. 202
12.20.1 COMPANY SNAPSHOT 202
12.20.2 REVENUE ANALYSIS 202
12.20.3 PRODUCT PORTFOLIO 202
12.20.4 RECENT DEVELOPMENT 203
12.21 SIEMENS 204
12.21.1 COMPANY SNAPSHOT 204
12.21.2 REVENUE ANALYSIS 204
12.21.3 PRODUCT PORTFOLIO 205
12.21.4 RECENT DEVELOPMENTS 206
?
12.22 SYSMEX CORPORATION 207
12.22.1 COMPANY SNAPSHOT 207
12.22.2 REVENUE ANALYSIS 207
12.22.3 PRODUCT PORTFOLIO 208
12.22.4 RECENT DEVELOPMENTS 208
12.23 THERMO FISHER SCIENTIFIC INC. 209
12.23.1 COMPANY SNAPSHOT 209
12.23.2 REVENUE ANALYSIS 209
12.23.3 PRODUCT PORTFOLIO 210
12.23.4 RECENT DEVELOPMENT 211
13 CONCLUSION 212
14 QUESTIONNAIRE 213
15 RELATED REPORTS 215